Anti-MDA5 dermatomyositis
MONDO:1010064A dermatomyositis characterized by the presence of anti-MDA5 autoantibodies. It is often associated with dermatomyositis rashes, amyopathic or hypomyopathic muscle involvement and interstitial lung disease, frequently as a rapid progressive course and high mortality.
Also known as: MDA-5 DM, MDA5+ DM, anti-melanoma differentiation-associated gene 5 dermatomyositis, clinically amyopathic dermatomyositis
15 clinical trials for this condition and its sub-types, 3 tagged with Anti-MDA5 dermatomyositis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a new pill ease muscle weakness in myositis?
Disease control Not yet recruitingThis phase III trial tests whether the oral drug nerandomilast can improve symptoms of idiopathic inflammatory myopathies, a group of rare autoimmune diseases that cause muscle weakness and inflammation. Adults with active myositis are randomly assigned to take nerandomilast or a…
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Promising drug could save lives in rare, deadly lung disease
Disease control Not yet recruitingThis study tests a drug called teclistamab in 24 adults with a severe, rapidly worsening lung disease linked to anti-MDA5 antibodies. The disease has a very poor outlook, with only about 25% of patients surviving 90 days without a lung transplant. Teclistamab aims to improve surv…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immune retraining: could CAR-Treg cells tame autoimmune disease?
Disease control Not yet recruitingThis early-phase study tests a new treatment called BEN301, which uses specially engineered immune cells (CAR-Tregs) to calm overactive immune responses in people with autoimmune diseases like scleroderma, rheumatoid arthritis, lupus, and inflammatory muscle disease. The trial wi…
Early phase 1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Can immune fingerprints unlock new treatments for skin disease?
Knowledge-focused Not yet recruitingThis observational study aims to map the immune and molecular profiles of people with inflammatory skin conditions, including genetic forms like epidermolysis bullosa. By comparing these profiles to those of healthy individuals, researchers hope to identify unique signatures that…
Sponsor: Guy's and St Thomas' NHS Foundation Trust • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC